Authors: Junot, C Pruvost, A Creminon, C Grognet, JM Benech, H Ezan, E

Citation: C. Junot et al., Characterization of immunoreactive acetyl-Ser-Asp-Lys-Pro in human plasma and urine by liquid chromatography-electrospray mass spectrometry, J CHROMAT B, 752(1), 2001, pp. 69-75

Authors: Junot, C Gonzales, MF Ezan, E Cotton, J Vazeux, G Michaud, A Azizi, M Vassiliou, S Yiotakis, A Corvol, P Dive, V

Citation: C. Junot et al., RXP 407, a selective inhibitor of the N-domain of angiotensin I-convertingenzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis, J PHARM EXP, 297(2), 2001, pp. 606-611

Authors: Struthers, AD MacFadyen, R Fraser, C Robson, J Morton, JJ Junot, C Ezan, E

Citation: Ad. Struthers et al., Nonadherence with angiotensin-converting enzyme inhibitor therapy - A comparison of different ways of measuring it in patients with chronic heart failure, J AM COL C, 34(7), 1999, pp. 2072-2077

Authors: Junot, C Nicolet, L Ezan, E Gonzales, MF Menard, J Azizi, M

Citation: C. Junot et al., Effect of angiotensin-converting enzyme inhibition on plasma, urine, and tissue concentrations of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro in rats, J PHARM EXP, 291(3), 1999, pp. 982-987

Authors: Junot, C Menard, J Gonzales, MF Michaud, A Corvol, P Ezan, E

Citation: C. Junot et al., In vivo assessment of captopril selectivity of angiotensin I-converting enzyme inhibition: Differential inhibition of acetyl-Ser-Asp-Lys-Pro and angiotensin I hydrolysis, J PHARM EXP, 289(3), 1999, pp. 1257-1261